21:17 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and rat studies identified a benzimidazole-based PTGER4 antagonist that could help treat pain. High throughput screening of Bayer AG's compound library, in vitro enzymatic activity assays and optimization of hits yielded...
21:28 , Dec 15, 2017 |  BioCentury  |  Finance

Kyndred spirits

Partners Kyn Therapeutics Inc. and Arrys Therapeutics Inc. share an investor syndicate and a focus on cancer therapies targeting metabolic pathways in immune cells. However, the companies are keeping their assets separate to keep the...
20:51 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

On Dec. 14, immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million,...
11:57 , Dec 14, 2017 |  BC Extra  |  Financial News

Kyn, Arrys raise series A rounds from Atlas, OrbiMed

Immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors. Arrys raised $21 million, while Kyn disclosed...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

RaQualia gastrointestinal news

CJ Group (Seoul, South Korea) has exclusive rights to RaQualia's RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia under a 2011 deal. In 2010, RaQualia granted CJ Group's CJ CheilJedang Co. affiliate exclusive rights...